Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P)
British Journal of Dermatology Feb 10, 2018
Langley RG, et al. - The experts evaluated the effect of a continuous every 2-week dosing (Q2W) of ixekizumab (an interleukin-17A antagonist) and every 4 weeks (Q4W) thereafter for the treatment of moderate-to-severe plaque psoriasis over a period of 52 weeks. Results illustrated a higher efficacy of ixekizumab Q2W at week 52 as compared to Q4W, without any increase in safety events.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
